I
Its use is intended for patients aged 55 years or older to help determine whether their cognitive impairment is due to Alzheimer’s disease.
It is designed to measure the ratio of beta amyloid 1–42 and beta-amyloid 1-40 concentrations in cerebral spinal fluid, which can help determine the likelihood of amyloid plaques in the brain.
It is not intended to be used as a screening or a stand-alone diagnostic assay because other neurological conditions, as well as older cognitively healthy people could have a positive result:it should be used only in conjunction with other clinical evaluations.
A clinical study found 97% of patients with a positive test had confirmed PET scan findings of amyloid plaques, and 84% of negative results correlated with a negative amyloid PET scan.